No photo of Young Kwang Chae

View Scopus Profile

Young Kwang Chae

  • 1884 Citations
20072025
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway

Training Experience

2011Residency, Albert Einstein Medical Center
2014Fellowship, University of Texas/MD Anderson Cancer Center

Education/Academic qualification

MBA, Johns Hopkins University

… → 2007

MPH, Johns Hopkins University

… → 2007

MD, Seoul National University

… → 2002

Research interests

  • Oncology

Fingerprint Dive into the research topics where Young Kwang Chae is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Neoplasms Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Hydroxymethylglutaryl-CoA Reductase Inhibitors Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2025

Prot #M16-573: A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

Chae, Y. K.

AbbVie Inc.

10/17/19 → 10/17/20

Project: Research project

Early Therapeutics and Rare Cancer Vice Chair Role

Chae, Y. K.

Oregon Health & Science University , National Cancer Institute

3/1/19 → 2/28/25

Project: Research project

Research Personnel
Neoplasms
Therapeutics
Strategic Planning
Mentoring

Prot #D6070C00004: A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated Advanced EGFRm NSCLC

Chae, Y. K.

ICON Clinical Research, LLC, MedImmune, LLC

12/3/18 → 12/3/21

Project: Research project

NU 17Z01 (Freenome) - Blood Biomarker Analysis in Patients with Solid Tumors or Lymphoma

Chae, Y. K.

Freenome Holdings, Inc.

12/21/17 → 12/21/20

Project: Research project

NU 17Z01 - Blood Biomarker Analysis in Patients with Solid Tumors or Lymphoma

Chae, Y. K.

Biodesix, Inc.

12/14/17 → 12/14/20

Project: Research project

Research Output 2007 2019

2 Citations (Scopus)

Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

Rich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., Subbiah, V., Trevarthen, D. R., Fairclough, S., Yen, J. & Gautschi, O., Jan 1 2019, In : Clinical Cancer Research. 25, 19, p. 5832-5842 11 p.

Research output: Contribution to journal › Article

Open Access
DNA
Gene Fusion
Neoplasms
Circulating Neoplastic Cells
Phase II Clinical Trials
7 Citations (Scopus)

A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors

Atrafi, F., Groen, H. J. M., Byers, L. A., Garralda, E., Lolkema, M. P., Sangha, R. S., Viteri, S., Chae, Y. K., Ross Camidge, D., Gabrail, N. Y., Hu, B., Tian, T., Nuthalapati, S., Hoening, E., He, L., Komarnitsky, P. & Calles, A., Jan 15 2019, In : Clinical Cancer Research. 25, 2, p. 496-505 10 p.

Research output: Contribution to journal › Article

Open Access
Carboplatin
Small Cell Lung Carcinoma
Etoposide
Neoplasms
Disease Progression
6 Citations (Scopus)

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N. A., Villaflor, V. M. & Giles, F., Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA Repair
Ligands
Mutation

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae, Y. K., Viveiros, P., Lopes, G., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., Ali, S. M., Ross, J. S., Chang, S., Wang, S., Chiec, L., Rahbari, A., Mohindra, N. A., Villaflor, V. M., Shin, S. H., Oh, M. & 5 others, Anker, J., Park, L. C., Wang, V., Chuang, J. & Park, W., Oct 1 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1807-1817 11 p.

Research output: Contribution to journal › Article

Frameshift Mutation
Lung Neoplasms
Tumor Burden
Atlases
Renal Cell Carcinoma
1 Citation (Scopus)

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T., Cruz, M. R., Tamragouri, K., Rhee, K., Mohindra, N. A., Villaflor, V. M., Park, W., Lopes, G. & Giles, F. J., Jun 1 2019, In : Oncologist. 24, 6, p. 820-828 9 p.

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Programmed Cell Death 1 Receptor